$70.97
1.37% yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US8064071025
Symbol
HSIC

Henry Schein Stock price

$70.97
-6.31 8.17% 1M
+6.41 9.93% 6M
-4.74 6.26% YTD
-4.45 5.90% 1Y
-5.27 6.91% 3Y
+4.70 7.09% 5Y
+17.12 31.79% 10Y
Nasdaq, Closing price Thu, Dec 26 2024
+0.96 1.37%
ISIN
US8064071025
Symbol
HSIC
Sector

Key metrics

Market capitalization $8.85b
Enterprise Value $13.18b
P/E (TTM) P/E ratio 29.06
EV/FCF (TTM) EV/FCF 28.60
EV/Sales (TTM) EV/Sales 1.05
P/S ratio (TTM) P/S ratio 0.71
P/B ratio (TTM) P/B ratio 2.54
Revenue growth (TTM) Revenue growth -1.53%
Revenue (TTM) Revenue $12.50b
EBIT (operating result TTM) EBIT $599.00m
Free Cash Flow (TTM) Free Cash Flow $461.00m
Cash position $126.00m
EPS (TTM) EPS $2.44
P/E forward 22.06
P/S forward 0.69
EV/Sales forward 1.03
Short interest 5.95%
Show more

Is Henry Schein a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Henry Schein Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Henry Schein forecast:

5x Buy
33%
6x Hold
40%
4x Sell
27%

Analyst Opinions

15 Analysts have issued a Henry Schein forecast:

Buy
33%
Hold
40%
Sell
27%

Financial data from Henry Schein

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
12,499 12,499
2% 2%
100%
- Direct Costs 8,797 8,797
2% 2%
70%
3,702 3,702
1% 1%
30%
- Selling and Administrative Expenses 2,814 2,814
5% 5%
23%
- Research and Development Expense - -
-
-
888 888
16% 16%
7%
- Depreciation and Amortization 289 289
25% 25%
2%
EBIT (Operating Income) EBIT 599 599
28% 28%
5%
Net Profit 314 314
29% 29%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Henry Schein directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Henry Schein Stock News

Neutral
Business Wire
10 days ago
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to participate at J.P. Morgan's Healthcare Investor Conference.
Positive
CNBC
about one month ago
Ananym Capital is calling for changes at Henry Schein, which may help the company improve its profitability.
Neutral
Business Wire
about one month ago
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to participate in investor conferences in December.
More Henry Schein News

Company Profile

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Head office United States
CEO Stanley Bergman
Employees 25,000
Founded 1932
Website www.henryschein.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today